PIA
GTHX

Piedmont Investment Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Piedmont Investment Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-354
Closed -$15K – 2397
2018
Q2 		$15K Buy
+354
New +$15.2K ﹤0.01% 1684

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Piedmont Investment Advisors's GTHX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2018, closing a stake of 354 shares — an estimated $15K sold.

Piedmont Investment Advisors first reported a position in GTHX in Q2 2018 and held it in 1 quarter. The position peaked at $15K in Q2 2018. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 354 G1 Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $15K.
  • Piedmont Investment Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $15K in Q2 2018.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.